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Abstract
In assisting a patient with adrenocortical tumors, the main concern is to 
establish whether the lesion consists of a malignant neoplasm and if there is any 
hormonal functioning, which are two instances that generally demand surgery. In 
distinguishing benign from malignant lesions, two aspects are particularly impor-
tant: the size of the lesion and the image findings. In order to establish whether a 
lesion is hormonally functioning, it is necessary to carry out thorough clinical and 
endocrine assessments. The extension of such assessments is still controversial. This 
present chapter revises fundamental aspects of the propaedeutic of such tumors. 
Most guidelines agree that lesions smaller than 1 cm need not be investigated. The 
diagnostic and therapeutic approach of adrenocortical tumors imposes a difficult 
and challenging dilemma in terms of its approach, as it may be a benign finding or it 
may imply a high level of morbidity and mortality due to its hormonal activity or a 
possible malignant histology.
Keywords: adrenocortical tumors, adenoma, adrenal, Cushing’s syndrome, 
aldosteronoma
1. Introduction
Adrenal gland tumors are common entities in clinical practice. They are divided 
as functioning (which produces hormones) and the nonfunctioning ones (also 
known as silent). In terms of their biological behavior, they may be divided in 
benign or malignant tumors. The term “incidentaloma” refers to adrenal masses 
that are found in image exams aiming at investigating disturbances unrelated to the 
adrenal glands [1–3].
Most adrenocortical tumors are benign, unilateral, nonfunctioning adenomas 
with less than 4 cm in diameter that are found during abdominal image studies [3]. 
The functioning adrenal tumors are generally the benign adenoma type, which 
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cause, for instance, the Cushing’s syndrome, primary aldosteronism, or, not so 
commonly, virilization [1, 2].
This present chapter discusses the preoperative assessment of patients suffering 
from this condition. It mainly focuses on:
1. Whether there is hormonal production by the tumor and the controlling 
techniques
2. The malignancy risk and the staging for propaedeutic planning purposes
2. Epidemiology
The frequency of adrenocortical tumor diagnosis has increased nowadays due 
to larger availability of image examination techniques, which makes it a relatively 
common clinical problem currently. Some studies claim a detection rate of 4% in all 
abdominal computer tomography [4]. Studies in series of autopsies identified that 
adrenal masses count less than 1% in individuals younger than 30 years of age and 
that the rate increases to 7% in those who were 70 or older [1, 2].
Adrenocortical tumors are more common in white, obese, diabetic, and 
hypertensive individuals. These data might be biased, as elderly, white individu-
als constitute the groups that most frequently undergo image examinations. It is 
known that such tumors are rather uncommon in individuals under 50 years of age 
and are especially uncommon in children [2]. They are more common on the right 
side [2, 3].
In terms of hormonal production, even though most tumors are nonfunctioning, in 
up to 15% of cases, there might be a slightly increased production of certain hormones, 
being cortisol the most common one, which may cause Cushing’s syndrome [1].
Around 10–15% of all tumors found are bilateral [2]. Bilateral functioning adre-
nocortical masses may be congenital adrenal hyperplasia due to a 21-hydroxylase 
deficiency, adrenal macronodular hyperplasia, or primary hyperaldosteronism [2].
The most common causes of bilateral nonfunctioning adrenal masses are metas-
tases, infections (mycosis, tuberculosis), lymphomas, bleedings, amyloidosis, and, 
rather rarely, carcinoma and myelolipomas [1].
In a decreasing order of occurrence, the adrenocortical tumor categories are:
1. Nonfunctioning adenomas (43–75%)
2. Cortisol-producing adenomas (including subclinical Cushing’s syndrome) 
(10–15%)
3. Myelolipomas (6–8%)
4. Adrenal carcinomas (4–11%)
5. Metastatic lesions (3–10%)
6. Aldosteronomas (2–6%)
7. Cyst (5%)
8. Tuberculosis and lymphomas (3–8%)
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3. Natural history
Natural history of adrenocortical tumors is still not completely known [1]. Some 
studies suggest that most incidentalomas remain within stable size for many years 
[2]. Long-term follow-up studies suggest that from 5 to 20% of cases involving 
tumors larger than 1 cm, there is an increase in adrenal mass after an average period 
of 4 years, regardless of the state of adrenal hormonal production [1]. The typical 
increase rate of an adrenocortical carcinoma exceeds 2 cm per year, with a survival 
expectation lower than 50% within 5 years [1, 2].
Occasionally, tumor reduction might be observed (3–4% of cases). Appearance 
of mass at the contralateral gland might also be noticed. Nonetheless, the risk of 
malignancy development is low (<1/1000) [1].
There is a risk that a nonfunctioning adenoma starts to produce some hormone 
during follow-up, especially if the mass is larger than 3 cm and mainly in the case of 
cortisol production. Prospective studies show a 0.3% risk of a subclinical Cushing’s 
syndrome development and a 0.2% chance of it turning into a pheochromocytoma. 
After a 3- to 4-year follow-up, such risk reaches a plateau that is to say the possibil-
ity that it would turn into a functioning one is low. Therefore, repetition of screen-
ing for functioning is only prescribed during the first 5 years of follow-up [2].
For the reasons explained here, rather small nodules (smaller than 1 cm) with 
a benign tomographic aspect need not be further investigated by image, as the 
benignity chance is high, whereas the risk of growth is low [2].
4. Pathological findings
Adrenal adenomas are generally encapsulated, have variable volume and weight, 
and in most cases have a diameter of 2–4 cm. In nonfunctioning tumors, clear cells 
of the fasciculate zone, filled with lipids (cholesterol), predominate microscopi-
cally, which gives the yellowish coloration. Functioning tumors are usually of varied 
colors, reddish-brown, with yellowish areas or striae, showing in microscopy the 
predominance of compact cells, associated with clear cell nests (Figure 1). Cortisol-
producing adenomas are accompanied by hypotrophy of the adrenal cortex of 
the affected gland and the contralateral adrenal gland due to adrenocorticotropic 
hormone (ACTH) (suppression in contrast to aldosterone-producing adenomas in 
which this aspect is not observed) [3].
Figure 1. 
Microscopy of an adrenal cortex adenoma showing one or more cell types (A) separated from each other 
by fibrous septa containing blood vessels (H&E 100×). High increase showing cells in the zona glomerulosa, 
fasciculate zone, and reticular zone forming nests and strands (H&E 400×).
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Adrenal carcinomas are usually larger than 4 cm and occasionally weigh more 
than 1 kg. Microscopically, the picture is varied: in some cases, the tumor is very 
similar to the adenoma, but in some cases, the tumor appears anaplastically, being 
composed of cells with large pleomorphism, bizarre nuclei, and atypical mitoses. 
Vascular or capsular invasion is a predictive sign of malignant behavior, being a sign 
of local extension [3, 4].
Differentiation with adenomas can be difficult and is based on macroscopic 
(tumor weight, hemorrhage, and capsule integrity) and microscopic aspects using 
the modified Weiss scoring system. The five criteria used in the updated Weiss sys-
tem include >6 mitoses/50 high potency fields, ≤25% clear tumor cells in the cyto-
plasm, abnormal mitoses, necrosis, and capsular invasion. Each criterion is scored 0 
when absent or 2 for the first two criteria and 1 for the last three when present. The 
adrenal carcinoma can be diagnosed by the presence of a total score ≥ 3 [5].
Tumors are functioning in approximately 60% of all cases, but the presence 
of symptoms of hormonal hypersecretion is present in only 40%, possibly by the 
secretion of large quantities of biologically inactive hormones [5, 6].
In general, adrenal carcinomas rarely produce and secrete a single steroid 
hormone and are usually associated with overproduction and hypersecretion of 
multiple hormones and precursors. Most cases produce different types of steroid 
hormones [7–9]. Thus, hypersecretion of a single adrenocortical steroid usually 
indicates the benign nature of adrenocortical neoplasia. The most frequently seen 
combination is hypersecretion of cortisol and androgens [10].
5. Hormone assessment
There are basically three types of production by adrenocortical tumors:
1. Cortisol (corresponding to between 5 and 20% of cases)
2. Aldosterone (corresponding to 1% of cases)
3. Androgen (extremely rare)
5.1 Cortisol-producing tumors
Such tumors generally produce minute quantities of cortisol, which, most 
of times, do not suffice to increase the excretion of free cortisol in urine. They 
are, nonetheless, able to cause suppression of the hypothalamic-pituitary axis. 
Ordinarily, there are no Cushing-related manifestations in those patients. For 
that reason, this condition has been known as subclinical Cushing’s syndrome or 
subclinical hypercortisolism [11]. There might be the classic Cushing’s syndrome in 
long-evolving cases.
A suppression test with 1 mg of dexamethasone should be carried out at night 
for tracking Cushing’s syndrome. The patient orally takes 1 mg of dexamethasone 
at 11:00 pm the night prior to sample collection of plasmatic cortisol, which is to 
be carried out at 8:00 am the following morning. Values that determine abnormal 
response of cortisol in this test varied in several studies from 1.8 to 5.0 mcg/dL, yet 
most guidelines lead to the following interpretation:
Levels of plasmatic cortisol <1.8 mcg/dL virtually exclude autonomous produc-
tion of cortisol, with sensitivity >95% and specificity from 70 to 80%.
Cortisol levels between 1.8 and 5 mcg/dL have been considered to be 
undetermined.
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Values >5 mcg/dL would indicate a highly probable diagnosis of Cushing’s 
syndrome (specificity > 95%) [1].
An abnormal suppression of 1 mg of dexamethasone during the night is consistent 
with a positive tracking, and it should be confirmed by a 24-hour free urinary corti-
sol, which should then be followed by an investigation of the serum dosage of cortisol 
after a high dose (8 mg) of dexamethasone during the night and the serum dosage 
ACTH [3, 4]. This latter investigation aims at determining the origin of the Cushing’s 
syndrome, as to refute a hypopituitary cause. This condition is typically presented 
with unsuppressed levels (ACTH dependent). For diagnosis of subclinical Cushing’s 
syndrome, many experts propose confirmation under the following criteria:
Values > 5 mcg/dL in plasmatic cortisol at the 1 mg dexamethasone test without 
any other stigma
OR
At least two from the following results:
Levels of plasmatic ACTH < 10 pg/ml with an increased 24-hour free urinary 
cortisol and values > 3 mcg/dL of plasmatic cortisol at the 1 mg dexamethasone test 
[1]. Figure 2 shows an algorithm of investigation of Cushing’s syndrome.
Dehydroepiandrosterone sulfate is an adrenal androgen that is produced under 
stimulus of ACTH. Thus, an undetectable concentration of dehydroepiandrosterone 
sulfate in serum suggests a chronical suppression of ACTH levels [12].
Percentage of patients suffering from subclinical Cushing’s syndrome that would 
evolve to the classic Cushing’s syndrome is uncertain. It is estimated to be <1%, 
though [1].
Even though patients suffering from subclinical Cushing’s syndrome do not 
present the classic stigmata related to hypercortisolism, they present, as suggested in 
some studies, in comparison with the population in general, higher occurrences of:
• Hypertension (40–90%)
• Type 2 diabetes mellitus or glucose intolerance (20–75%)
• Osteopenia/osteoporosis (40–50%)
• Hyperlipidemia (50%)
• Obesity (35–50%)
An increase in the carotid intima-media thickness has been recently reported, 
as well as alteration of coagulation parameters, decrease in the quality of life, and 
occurrences of mortality due to cardiovascular disease [1].
For those reasons, there is still no consensus about the approach to subclinical 
Cushing’s syndrome. It may be treated clinically or through surgery [2].
Generally, in cases with many occurrences of comorbidity that might be attrib-
uted to hypercortisolism, such as systemic arterial hypertension, diabetes mellitus, 
dyslipidemia, osteoporosis, and central obesity, especially the ones that are difficult 
to control, a ponderation of the risk/benefit of surgical treatment by adrenalectomy 
of the affected adrenal should be carried out, as proposed for the treatment of clas-
sic Cushing’s syndrome [2].
It is important to mention that up to 75% of patients might develop acute adrenal 
insufficiency (sometimes deadly) at the post-surgery phase of adrenalectomy in 
case they are not treated with glucocorticoid due to atrophy of the contralateral 
gland. This should be an additional functional endocrine characterization for the 
propaedeutic planning [1]. In case the adrenalectomy is carried out, there should be 
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a perioperative coverage of glucocorticoid due to the risk of adrenal insufficiency, 
hemodynamic crisis, and death [12].
Weight loss, improvement of hypertension, glycemic control, and normalization 
of bone renewal markers are frequently found in the post unilateral adrenalectomy 
scenario of patients with subclinical or classic Cushing’s syndrome [12].
5.2 Aldosterone-producing tumors
Also known as aldosteronomas, they are rare (less than 1% of cases), and 
their characteristic manifestation is systemic arterial hypertension associated 
with hypokalemia. Yet primary normocalcemic hyperaldosteronism is common 
(20–50% of cases) [1, 12]. For that reason, as most patients suffering from 
primary aldosteronism do not suffer from hypocalcemia, all patients suffer-
ing from hypertension and adrenal incidentaloma should be assessed through 
measurements of their aldosterone plasmatic concentration and plasma renin 
activity [12].
Initial endocrine investigation in such cases consists of dosing the levels of 
plasma aldosterone and plasma renin activity. In case the ratio between them is <27, 
the existence of hyperaldosteronism is virtually excluded. Other authors use further 
landmarks (between 20 and 30) to establish diagnosis as abnormal. Values >40–50 
are almost hyperaldosteronism pathognomonic [1].
It is important to mention that if the laboratory can only assess the renin direct 
dosage (other than the plasma renin activity), the renin value must be divided by 
12, so that the actual value of plasma renin activity is established, which will even-
tually be the one used for the ratio calculation. If the ratio is lower than 20, it can 
refute diagnosis. In case it is between 20 and 30, it indicates a likely diagnosis. Then, 
if it exceeds 30, with aldosterone dosage higher than 15 ng/dl, positive tracing 
should be considered and investigation should continue through tests for confirma-
tion [2]. In patients with spontaneous hypokalemia, plasma renin below detection 
Figure 2. 
An algorithm for investigation of Cushing’s syndrome in adrenal incidentalomas. Dexa, dexamethasone; SC, 
serum cortisol; UFC, urine-free cortisol; ACTH, adrenocorticotropic hormone. *At least two measurements.
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levels plus plasma aldosterone >20 ng/dL, it is suggested that there is no need for 
further confirmatory testing (Figure 3) [4].
The aldosterone and plasma renin activity relationship should never be used for 
patients under spironolactone, and in case doubtful results appear, other medica-
tions (a beta blocker, central alpha-adrenergic agonist, anti-inflammatory) that 
might cause a false increase of that relationship should ideally be suspended, as well 
as those drugs that cause a false reduction of the inhibitors of angiotensin-converting 
enzyme, aldosterone receptor blocker, thiazide, and dihydropyridine inhibitors of 
the calcium channel [2].
Patients older than 40 years of age suffering from confirmed hyperaldosteron-
ism, even with evidence of adrenal images compactible with such diagnosis, should 
be submitted to adrenal catheterization for assessment of whether that increased 
aldosterone production is really due to incidentaloma or to adrenal hyperplasia, 
whereas the occurrence of nonfunctioning incidentalomas in the population older 
than 40 is no longer negligible (around 4%).
In such cases, adrenalectomy would not solve hormonal hyperproduction, which 
should be kept under control with the use of medication, aldosterone antagonists, 
such as spironolactone [2].
5.3 Androgen- and estrogen-producing tumors
In cases of congenital adrenal hyperplasia due to a 21-hydroxylase deficiency, it 
is rather common to find adrenal masses, either uni- or bilateral ones, presumably 
due to excessive chronic stimulation of adrenals by ACTH [1].
Sex-hormone-producing adrenal adenomas are very rare. Androgen-producing 
carcinomas are also uncommon. Nevertheless, patients generally manifest some 
virilization, which makes it unlikely for such tumors to be related to adrenal 
incidentalomas. Thus, the routine testosterone and estradiol dosage are not rec-
ommended for patients with adrenocortical incidentalomas who present trace of 
Figure 3. 
Algorithm for investigation of hyperaldosteronism in adrenal incidentalomas. *Most commonly used 
confirmatory tests: oral sodium loading test and intravenous saline infusion test. #In patients with spontaneous 
hypokalemia, plasma renin below detection levels plus plasma aldosterone > 20 ng/dl, it is suggested that there 
is no need for further confirmatory testing.
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virilization [1]. For individuals that present such virilization or high concentrations 
of androgens, adrenalectomy may be indicated for controlling of hormones.
Estrogen-producing tumors are rare and they are generally malignant. In men, it 
may manifest through feminization with gynecomastia, decrease in libido, atrophy 
of testicles, whereas in women, it could manifest through breast sensitivity and 
bleedings [12]. In such cases, adrenalectomy may also be indicated.
6. Adrenal image
As previously mentioned, most adrenocortical tumors are benign, nonfunction-
ing adenomas that were incidentally found in abdominal image examinations such 
as computed tomography and abdomen magnetic resonance imaging.
Adrenal incidentalomas rarely have a malign cause in patients with no known 
record of cancer. It is estimated that only 2–5% of incidentalomas are formed by 
adrenal adenocarcinomas, and around 0.7–2.5% of cases are caused by metastasis 
from tumors elsewhere toward the adrenal [13, 14].
Size and some other radiology characteristics of the computed tomography and 
magnetic resonance imaging might help differentiating an adrenal benign lesion from a 
malign one, with consequent perioperative implications. Adrenal tumors with surgical 
indication are generally approached through laparoscopy. On the other hand, in cases 
when an adrenal adenocarcinoma is suspected, open surgery is preferable, especially 
for larger lesions (>10 cm), or for those that might expand to other organs [15].
There is a direct relationship between the size of the adrenal tumor and the 
potential for malignancy. Average size of an adrenal adenocarcinoma at diagnosis 
is 10–11 cm, whereas most benign adrenal tumors present a diameter smaller than 
5 cm [16].
Besides their larger size, malign adrenal tumors, in most cases, show on image 
exams as heterogeneous lesions, with irregular margins, suggestive calcifications, 
and a peripheral enhancement by intravenous contrast due to the core of the 
necrosis. Expansion toward other organs and lymph node involvement confirm 
malignancy.
Adrenal adenomas feature a profuse presence of lipids in their constitution. It is, 
therefore, very useful to assess the lipid contents by means of density calculation for 
differentiating adrenal tumors [15].
6.1 Computed tomography
The computed tomography is a very important exam in assessing adrenal tumors. 
At the phase with no contrast, a density calculus is used by means of the Hounsfield 
units (UH). Lesions with a <10 UH density have a high probability of being benign, 
whereas most adrenal adenocarcinomas present a >30 UH, which indicates low lipid 
content. Thus, tumors with density >10 UH demand further assessment.
Precision of diagnosis may be enhanced by the use of late stages of computed 
tomography with contrast and the “washout” calculation, which represents the 
fraction of contrast that is eliminated 10 min after administration. The finding 
of an average absolute “washout” of 50% after 10 min of contrast used in studies 
evidenced a 100% sensitivity and specificity for detection of adenomas in relation 
to adenocarcinomas, pheochromocytoma, and extra-adrenal metastases [17, 18].
All patients likely to be suffering from an adrenal adenocarcinoma should 
undergo a computed tomography of the thorax prior to surgery as any findings 
related to metastasis may alter the approach of treatment.
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6.2 Magnetic resonance imaging
Despite the fact that the computed tomography is the most important exam in 
assessing adrenal nodules, in some situations it is imperative to resort to a magnetic 
resonance imaging.
Analysis of conventional images weighted at T1 and T2 is the most frequently 
used technique. Adrenal adenocarcinomas present an isointense sign in relation to 
the T1 liver and enhanced intensity of sign at weighted sequences at T2 (Figure 4). 
Typically, they present as large lesions (>5.0 cm) at the moment of the diagnosis 
and may include necrosis, bleeding, and, frequently, calcification [19].
After administration of gadolinium, a slight increase of sign is noticed, as well 
as a swift washout of contrast, whereas malign lesions present a fast and striking 
increase of sign followed by a rather slow washout pattern [20].
Chemical shift imaging is a detection technique for the presence of lipids. 
Benign lesions show as relatively shiny at the in-phase images, and they present 
a dimmed sign at the out-of-phase ones. The majority of adenomas are slightly 
hypointense or isointense to the liver on T1-weighted images and slightly hyper-
intense or isointense on T2-weighted images. The utilization of chemical shift 
techniques (in-phase or out-of-phase GRE) allows the characterization of adenomas 
containing microscopic fat and water protons in a same voxel (Figure 5). On out-of-
phase images, the protons signal is null and results in signal loss as compared with 
in-phase images [21–24].
A magnetic resonance imaging may be superior to a computed tomography in 
the assessment of the vascular invasion, especially in terms of the inferior vena cava 
[25, 26].
6.3 Other resources of diagnosis per image
In patients whose characterization of lesion malignancy could not be carried out 
by a tomography or resonance, additional information could be obtained through 
fluorine-18 fluorodeoxyglucose positron emission tomography. Malignant lesions 
present a high collection rate of the radiotracer.
Metomidate binds itself specifically to Cyp11b cortical adrenal enzymes. It 
is used as a radiotracer at C-MTO PET, as it is capable of differentiating lesions 
originated at the adrenal cortical from the metastatic ones toward the adrenal [27].
Figure 4. 
Adrenal cortical carcinoma. Magnetic resonance imaging coronal T2-weighted FSE (A) and contrast-enhanced 
axial T1-weighted GRE (B) sequences demonstrate a large expansive lesion involving the right adrenal 
gland. The lesion shows heterogeneous pattern of impregnation by the contrast agent and areas of necrosis 
(hypersignal on T2-weighted sequences) (arrows).
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7. Conclusion
Patients diagnosed with adrenal lesions should undergo a thorough assessment 
of functioning in light of the possibility of malignancy.
Functioning adrenal tumors or those likely to be malignant should lead to surgi-
cal treatment.
Special care should be taken in preparation prior to adrenalectomy of patients 
that might suffer from functioning tumors or pheochromocytoma.
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ACTH adrenocorticotropic hormone
UH Hounsfield units
H&E hematoxylin and eosin
SC serum cortisol
UFC urine-free cortisol
FSE fast spin echo
GRE gradient echo
Figure 5. 
Magnetic resonance imaging axial T1-weighted phase GRE (A) and axial out-of-phase sequences  
(B) demonstrate right adrenal lesions signal loss (arrows), allowing the diagnosis of microscopic lipid-rich 
adenoma.
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